Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.11
-0.12-0.70%
At close: -
$17.19
0.080.47%
After Hours: 7:34 PM EDT
Comments
Loading...
Sarepta Therapeutics Analyst Ratings and Price Targets | NASDAQ:SRPT | Benzinga
Sarepta Therapeutics Inc has a consensus price target of $74.48 based on the ratings of 27 analysts. The high is $230 issued by Leerink Partners on June 24, 2024. The low is $10 issued by HC Wainwright & Co. on June 25, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Oppenheimer, and Mizuho on June 25, 2025, June 20, 2025, and June 18, 2025, respectively. With an average price target of $31.67 between HC Wainwright & Co., Oppenheimer, and Mizuho, there's an implied 84.22% upside for Sarepta Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
Mizuho
Deutsche Bank
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Sarepta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2025 | Buy Now | -41.83% | HC Wainwright & Co. | Mitchell Kapoor46% | $40 → $10 | Downgrade | Neutral → Sell | Get Alert |
| 06/20/2025 | Buy Now | 161.78% | Oppenheimer | Hartaj Singh44% | $123 → $45 | Maintains | Outperform | Get Alert |
| 06/20/2025 | Buy Now | — | William Blair | Sami Corwin18% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/18/2025 | Buy Now | 132.69% | Mizuho | Uy Ear59% | $85 → $40 | Maintains | Outperform | Get Alert |
| 06/17/2025 | Buy Now | 45.43% | Deutsche Bank | David Hoang41% | $50 → $25 | Maintains | Hold | Get Alert |
| 06/17/2025 | Buy Now | 68.7% | Goldman Sachs | Salveen Richter51% | → $29 | Downgrade | Buy → Neutral | Get Alert |
| 06/17/2025 | Buy Now | 132.69% | Morgan Stanley | Matthew Harrison60% | $113 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 06/17/2025 | Buy Now | 74.52% | Baird | Brian Skorney58% | $60 → $30 | Maintains | Outperform | Get Alert |
| 06/17/2025 | Buy Now | 336.3% | Wells Fargo | Yanan Zhu43% | $100 → $75 | Maintains | Overweight | Get Alert |
| 06/17/2025 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Initiates | → Peer Perform | Get Alert |
| 06/17/2025 | Buy Now | 68.7% | Barclays | Gena Wang51% | $89 → $29 | Maintains | Overweight | Get Alert |
| 06/16/2025 | Buy Now | 214.14% | Jefferies | Andrew Tsai27% | $125 → $54 | Maintains | Buy | Get Alert |
| 06/16/2025 | Buy Now | 62.89% | B of A Securities | Tazeen Ahmad56% | $76 → $28 | Downgrade | Buy → Neutral | Get Alert |
| 06/16/2025 | Buy Now | 307.21% | BMO Capital | Kostas Biliouris34% | $120 → $70 | Downgrade | Outperform → Market Perform | Get Alert |
| 06/16/2025 | Buy Now | 109.42% | Piper Sandler | Biren Amin40% | $70 → $36 | Downgrade | Overweight → Neutral | Get Alert |
| 06/16/2025 | Buy Now | 190.87% | Needham | Gil Blum51% | $125 → $50 | Maintains | Buy | Get Alert |
| 06/16/2025 | Buy Now | -41.83% | HC Wainwright & Co. | Mitchell Kapoor46% | $40 → $10 | Downgrade | Neutral → Sell | Get Alert |
| 06/06/2025 | Buy Now | 365.39% | Scotiabank | Louise Chen56% | $80 → $80 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 05/22/2025 | Buy Now | 132.69% | HC Wainwright & Co. | Raghuram Selvaraju44% | $40 → $40 | Reiterates | Neutral → Neutral | Get Alert |
| 05/20/2025 | Buy Now | 388.66% | JP Morgan | Anupam Rama59% | $169 → $84 | Maintains | Overweight | Get Alert |
| 05/08/2025 | Buy Now | 481.73% | Wells Fargo | Yanan Zhu43% | $115 → $100 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 417.74% | Barclays | Gena Wang51% | $209 → $89 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 237.41% | RBC Capital | Brian Abrahams49% | $87 → $58 | Maintains | Sector Perform | Get Alert |
| 05/07/2025 | Buy Now | 481.73% | Goldman Sachs | Salveen Richter51% | $178 → $100 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 470.1% | Guggenheim | Debjit Chattopadhyay55% | $112 → $98 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 307.21% | Piper Sandler | Biren Amin40% | $110 → $70 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 615.53% | Oppenheimer | Hartaj Singh44% | $184 → $123 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 371.2% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $81 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 132.69% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $40 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 557.36% | Morgan Stanley | Matthew Harrison60% | $182 → $113 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 627.17% | Needham | Gil Blum51% | $183 → $125 | Maintains | Buy | Get Alert |
| 04/21/2025 | Buy Now | 539.91% | Piper Sandler | Biren Amin40% | $182 → $110 | Maintains | Overweight | Get Alert |
| 04/16/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/11/2025 | Buy Now | 958.76% | Morgan Stanley | Matthew Harrison60% | $196 → $182 | Maintains | Overweight | Get Alert |
| 04/11/2025 | Buy Now | 568.99% | Wells Fargo | Yanan Zhu43% | → $115 | Initiates | → Overweight | Get Alert |
| 04/07/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/04/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Neutral → Neutral | Get Alert |
| 04/03/2025 | Buy Now | 964.57% | Needham | Gil Blum51% | $202 → $183 | Maintains | Buy | Get Alert |
| 04/02/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Upgrade | Sell → Neutral | Get Alert |
| 03/31/2025 | Buy Now | 406.11% | RBC Capital | Brian Abrahams49% | $161 → $87 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/20/2025 | Buy Now | 365.39% | Scotiabank | Louise Chen56% | $105 → $80 | Maintains | Sector Perform | Get Alert |
| 03/19/2025 | Buy Now | 848.23% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/19/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 03/19/2025 | Buy Now | 475.92% | Deutsche Bank | David Hoang41% | $124 → $99 | Maintains | Hold | Get Alert |
| 03/18/2025 | Buy Now | 1075.1% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 848.23% | Cantor Fitzgerald | Kristen Kluska71% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 510.82% | Scotiabank | Louise Chen56% | → $105 | Initiates | → Sector Perform | Get Alert |
| 02/27/2025 | Buy Now | 836.59% | RBC Capital | Brian Abrahams49% | $165 → $161 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 1075.1% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 02/13/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/30/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Raghuram Selvaraju44% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/27/2025 | Buy Now | 1075.1% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 01/14/2025 | Buy Now | 1075.1% | Needham | Gil Blum51% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $75 → $75 | Reiterates | Sell → Sell | Get Alert |
| 12/03/2024 | Buy Now | 336.3% | HC Wainwright & Co. | Mitchell Kapoor46% | $80 → $75 | Maintains | Sell | Get Alert |
| 11/27/2024 | Buy Now | 958.76% | Piper Sandler | Biren Amin40% | $200 → $182 | Maintains | Overweight | Get Alert |
| 11/27/2024 | Buy Now | 1075.1% | Needham | Gil Blum51% | $205 → $202 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 365.39% | HC Wainwright & Co. | Mitchell Kapoor46% | → $80 | Initiates | → Sell | Get Alert |
| 11/07/2024 | Buy Now | 1115.82% | Barclays | Gena Wang51% | $203 → $209 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 772.6% | Guggenheim | Whitney Ijem56% | $148 → $150 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 1022.75% | Baird | Brian Skorney58% | $200 → $193 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 871.5% | Cantor Fitzgerald | Kristen Kluska71% | $152 → $167 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 888.95% | Evercore ISI Group | Gavin Clark-Gartner38% | $179 → $170 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 1092.55% | Needham | Gil Blum51% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | 958.76% | RBC Capital | Brian Abrahams49% | $182 → $182 | Reiterates | Outperform → Outperform | Get Alert |
| 10/21/2024 | Buy Now | 859.86% | Jefferies | Andrew Tsai27% | → $165 | Initiates | → Buy | Get Alert |
| 10/14/2024 | Buy Now | 1092.55% | Needham | Gil Blum51% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 772.6% | Raymond James | Danielle Brill41% | → $150 | Reinstates | → Outperform | Get Alert |
| 10/04/2024 | Buy Now | 958.76% | RBC Capital | Brian Abrahams49% | $181 → $182 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 784.24% | Cantor Fitzgerald | Kristen Kluska71% | $152 → $152 | Reiterates | Neutral → Neutral | Get Alert |
| 09/19/2024 | Buy Now | 952.94% | RBC Capital | Brian Abrahams49% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 09/06/2024 | Buy Now | 952.94% | RBC Capital | Brian Abrahams49% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | 952.94% | RBC Capital | Brian Abrahams49% | $181 → $181 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 952.94% | RBC Capital | Brian Abrahams49% | $182 → $181 | Maintains | Outperform | Get Alert |
| 08/08/2024 | Buy Now | 830.77% | Citigroup | David Hoang41% | $176 → $160 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 784.24% | Cantor Fitzgerald | Kristen Kluska71% | $167 → $152 | Maintains | Neutral | Get Alert |
| 08/08/2024 | Buy Now | 1063.47% | Piper Sandler | Biren Amin40% | $205 → $200 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | 941.3% | Evercore ISI Group | Gavin Clark-Gartner38% | $185 → $179 | Upgrade | In-Line → Outperform | Get Alert |
| 08/08/2024 | Buy Now | 1080.92% | Barclays | Gena Wang51% | $226 → $203 | Maintains | Overweight | Get Alert |
| 07/29/2024 | Buy Now | 958.76% | RBC Capital | Brian Abrahams49% | → $182 | Upgrade | Sector Perform → Outperform | Get Alert |
| 07/01/2024 | Buy Now | 1092.55% | Piper Sandler | Biren Amin40% | $205 → $205 | Maintains | Overweight | Get Alert |
| 06/27/2024 | Buy Now | 1267.07% | Needham | Gil Blum51% | $235 → $235 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2024 | Buy Now | 923.85% | Citigroup | David Hoang41% | $172 → $176 | Downgrade | Buy → Neutral | Get Alert |
| 06/24/2024 | Buy Now | 1063.47% | Morgan Stanley | Matthew Harrison60% | $165 → $200 | Maintains | Overweight | Get Alert |
| 06/24/2024 | Buy Now | 976.21% | Evercore ISI Group | Gavin Clark-Gartner38% | $139 → $185 | Maintains | In-Line | Get Alert |
| 06/24/2024 | Buy Now | 1063.47% | BMO Capital | Kostas Biliouris34% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/24/2024 | Buy Now | 1237.99% | Leerink Partners | Mani Foroohar50% | $165 → $230 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 859.86% | Morgan Stanley | Matthew Harrison60% | $165 → $165 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2024 | Buy Now | 813.32% | Piper Sandler | Biren Amin40% | $157 → $157 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 644.62% | Cantor Fitzgerald | Kristen Kluska71% | $128 → $128 | Reiterates | Neutral → Neutral | Get Alert |
| 06/21/2024 | Buy Now | 958.76% | RBC Capital | Brian Abrahams49% | $142 → $182 | Maintains | Sector Perform | Get Alert |
| 06/21/2024 | Buy Now | 1214.72% | Barclays | Gena Wang51% | $185 → $226 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | 1063.47% | Baird | Brian Skorney58% | $170 → $200 | Maintains | Outperform | Get Alert |
| 06/21/2024 | Buy Now | 1139.09% | B of A Securities | Tazeen Ahmad56% | $166 → $213 | Maintains | Buy | Get Alert |
| 06/21/2024 | Buy Now | 1267.07% | Needham | Gil Blum51% | $166 → $235 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 888.95% | BMO Capital | Kostas Biliouris34% | $170 → $170 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 888.95% | BMO Capital | Kostas Biliouris34% | $170 → $170 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 813.32% | Piper Sandler | Biren Amin40% | → $157 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Sarepta Therapeutics (SRPT) stock?
The latest price target for Sarepta Therapeutics (NASDAQ:SRPT) was reported by HC Wainwright & Co. on June 25, 2025. The analyst firm set a price target for $10.00 expecting SRPT to fall to within 12 months (a possible -41.83% downside). 83 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sarepta Therapeutics (SRPT)?
The latest analyst rating for Sarepta Therapeutics (NASDAQ:SRPT) was provided by HC Wainwright & Co., and Sarepta Therapeutics downgraded their sell rating.
When was the last upgrade for Sarepta Therapeutics (SRPT)?
The last upgrade for Sarepta Therapeutics Inc happened on June 6, 2025 when Scotiabank raised their price target to $80. Scotiabank previously had a sector perform for Sarepta Therapeutics Inc.
When was the last downgrade for Sarepta Therapeutics (SRPT)?
The last downgrade for Sarepta Therapeutics Inc happened on June 25, 2025 when HC Wainwright & Co. changed their price target from $40 to $10 for Sarepta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sarepta Therapeutics (SRPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sarepta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sarepta Therapeutics was filed on June 25, 2025 so you should expect the next rating to be made available sometime around June 25, 2026.
Is the Analyst Rating Sarepta Therapeutics (SRPT) correct?
While ratings are subjective and will change, the latest Sarepta Therapeutics (SRPT) rating was a downgraded with a price target of $40.00 to $10.00. The current price Sarepta Therapeutics (SRPT) is trading at is $17.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
